DK1803468T3 - Midler til behandling af glaukomatøs retinopati og optisk neuropati - Google Patents
Midler til behandling af glaukomatøs retinopati og optisk neuropatiInfo
- Publication number
- DK1803468T3 DK1803468T3 DK07105047.0T DK07105047T DK1803468T3 DK 1803468 T3 DK1803468 T3 DK 1803468T3 DK 07105047 T DK07105047 T DK 07105047T DK 1803468 T3 DK1803468 T3 DK 1803468T3
- Authority
- DK
- Denmark
- Prior art keywords
- agents
- optic neuropathy
- nrf2
- metabolites
- glaucomatous retinopathy
- Prior art date
Links
- 206010061323 Optic neuropathy Diseases 0.000 title abstract 2
- 208000017442 Retinal disease Diseases 0.000 title abstract 2
- 206010038923 Retinopathy Diseases 0.000 title abstract 2
- 208000020911 optic nerve disease Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 abstract 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 abstract 1
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000004258 Ethoxyquin Substances 0.000 abstract 1
- 238000006845 Michael addition reaction Methods 0.000 abstract 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 abstract 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
- 230000001120 cytoprotective effect Effects 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- 239000012039 electrophile Substances 0.000 abstract 1
- 235000019285 ethoxyquin Nutrition 0.000 abstract 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940093500 ethoxyquin Drugs 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 150000002540 isothiocyanates Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005937 nuclear translocation Effects 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 239000002676 xenobiotic agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53177003P | 2003-12-22 | 2003-12-22 | |
| EP04814825A EP1696958B1 (en) | 2003-12-22 | 2004-12-17 | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1803468T3 true DK1803468T3 (da) | 2011-12-05 |
Family
ID=34738696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07105047.0T DK1803468T3 (da) | 2003-12-22 | 2004-12-17 | Midler til behandling af glaukomatøs retinopati og optisk neuropati |
| DK04814825T DK1696958T3 (da) | 2003-12-22 | 2004-12-17 | Midler til behandling af glaukomatös retinopati og optiske neuropati |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04814825T DK1696958T3 (da) | 2003-12-22 | 2004-12-17 | Midler til behandling af glaukomatös retinopati og optiske neuropati |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050137146A1 (da) |
| EP (2) | EP1803468B1 (da) |
| JP (2) | JP4755599B2 (da) |
| KR (1) | KR20060127043A (da) |
| CN (1) | CN1897972A (da) |
| AT (2) | ATE523208T1 (da) |
| AU (1) | AU2004308919B2 (da) |
| BR (1) | BRPI0417987A (da) |
| CA (1) | CA2547852A1 (da) |
| CY (2) | CY1106623T1 (da) |
| DE (1) | DE602004005617T2 (da) |
| DK (2) | DK1803468T3 (da) |
| ES (2) | ES2371364T3 (da) |
| MX (1) | MXPA06006980A (da) |
| PL (2) | PL1803468T3 (da) |
| PT (2) | PT1696958E (da) |
| SI (2) | SI1696958T1 (da) |
| WO (1) | WO2005063295A1 (da) |
| ZA (1) | ZA200604862B (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881198B2 (en) * | 2001-01-09 | 2005-04-19 | J. David Brown | Glaucoma treatment device and method |
| DE602004005617T2 (de) * | 2003-12-22 | 2007-12-13 | Alcon Inc. | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
| US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
| JPWO2006030907A1 (ja) * | 2004-09-16 | 2008-05-15 | レドックス・バイオサイエンス株式会社 | 網膜保護剤 |
| CA2621993A1 (en) * | 2005-09-16 | 2007-03-29 | Bg Implant, Inc. | Glaucoma treatment devices and methods |
| WO2008016095A1 (en) * | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| EP2086318A4 (en) * | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS |
| JP2008247898A (ja) * | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| KR101665042B1 (ko) | 2008-04-18 | 2016-10-11 | 리타 파마슈티컬스 잉크. | 소염성 골격군을 포함하는 화합물 및 사용 방법 |
| BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
| US8124799B2 (en) | 2008-04-18 | 2012-02-28 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| AU2011240690C1 (en) | 2010-04-12 | 2014-11-06 | Reata Pharmaceuticals Holdings, LLC | Method of treating obesity using antioxidant inflammation modulators |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| US20130288985A1 (en) * | 2010-07-15 | 2013-10-31 | The Schepens Eye Research Institute Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| RU2447864C1 (ru) * | 2010-09-15 | 2012-04-20 | Инна Витальевна Щербинина | Способ лечения заболеваний зрительного нерва и сетчатки |
| CA2840003A1 (en) * | 2011-06-21 | 2012-12-27 | Ahmet Hoke | Compounds for treating peripheral neuropathies and other neurodegenerative disorders |
| RU2546019C2 (ru) * | 2013-03-02 | 2015-04-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ лечения глаукомной оптической нейропатии |
| EP2991621B1 (en) | 2013-05-02 | 2020-12-09 | Retina Foundation of the Southwest | Two-layer ocular implant |
| JP7030516B2 (ja) | 2014-12-31 | 2022-03-07 | マイクロオプティクス インコーポレイテッド | 緑内障治療装置および方法 |
| AU2016331925B2 (en) | 2015-09-30 | 2021-04-22 | Microoptx Inc. | Dry eye treatment devices and methods |
| EP3509642A1 (en) | 2016-09-12 | 2019-07-17 | ST IP Holding AG | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
| AU2017322544B2 (en) | 2016-09-12 | 2022-06-02 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| MA46749A (fr) | 2016-11-08 | 2019-09-18 | Reata Pharmaceuticals Inc | Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier |
| RU2647324C1 (ru) * | 2017-04-24 | 2018-03-15 | Игорь Евгеньевич Хаценко | Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата |
| AU2020440834A1 (en) * | 2020-03-30 | 2022-09-22 | Wuhan Neurophth Biotechnology Limited Company | Expression vector of human nuclear factor E2-related factor 2 and application of expression vector |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) * | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| US4678783B1 (en) * | 1983-11-04 | 1995-04-04 | Asahi Chemical Ind | Substituted isoquinolinesulfonyl compounds |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| CA2175985A1 (en) * | 1995-05-10 | 1996-11-11 | Yoichi Kiyosuke | Pharmaceutical composition containing substance inhibiting hsp47 production |
| JP3193301B2 (ja) * | 1995-09-14 | 2001-07-30 | 麒麟麦酒株式会社 | 生理活性タンパク質ｐ１６０ |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| US5681854A (en) * | 1995-11-22 | 1997-10-28 | Alcon Laboratories, Inc. | Use of aliphatic carboxylic acid derivatives in ophthalmic disorders |
| US6271224B1 (en) * | 1995-12-21 | 2001-08-07 | Alcon Laboratories, Inc. | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia |
| PT885888E (pt) * | 1996-02-02 | 2003-12-31 | Western Therapeutics Inst D | Derivados e farmacos de isoquinolina |
| US6586425B2 (en) * | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| JP3872834B2 (ja) * | 1996-03-04 | 2007-01-24 | 第一製薬株式会社 | メイラード反応抑制剤 |
| SI0956865T2 (sl) * | 1996-08-12 | 2011-04-29 | Mitsubishi Pharma Corp | Zdravila, ki obsegajo inhibitor Rho-kinaze |
| US5759787A (en) * | 1996-08-26 | 1998-06-02 | Tularik Inc. | Kinase assay |
| EP0977578B1 (en) * | 1997-01-16 | 2004-03-31 | University Of Florida Research Foundation, Inc. | Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| US6573044B1 (en) * | 1997-08-07 | 2003-06-03 | The Regents Of The University Of California | Methods of using chemical libraries to search for new kinase inhibitors |
| US6441033B1 (en) * | 1997-12-22 | 2002-08-27 | Alcon Manufacturing, Ltd. | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists |
| US6274338B1 (en) * | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| AU2440599A (en) * | 1998-02-25 | 1999-09-15 | Shionogi & Co., Ltd. | Therapeutic agent for complication of diabetes |
| US20010041174A1 (en) * | 1998-11-24 | 2001-11-15 | Najam Sharif | Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases |
| US6020383A (en) * | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| GB0030727D0 (en) * | 2000-12-15 | 2001-01-31 | Lumitech Uk Ltd | Methods and kits for detecting kinase activity |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| CA2357265C (en) * | 2001-04-24 | 2004-04-13 | University Of British Columbia | Improved additive for livestock feeds |
| US6884816B2 (en) * | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| DE60234052D1 (de) * | 2001-12-18 | 2009-11-26 | Brassica Foundation For Chemop | Vorbeugung und behandlung von oxidativer-stress-erkrankungen mit verbindungen die den intrazellulären spiegel von glutathion oder phase-ii-entgiftungsenzymen erhöhen |
| JP2005526719A (ja) * | 2002-02-15 | 2005-09-08 | ディーエスエム アイピー アセッツ ビー．ブイ． | 血管新生関連病状の治療および予防のための、リコペンを含む組成物 |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| EP1545493A4 (en) * | 2002-08-05 | 2006-01-11 | Wackvom Ltd | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NEOVASCULARIZATION |
| US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
| MXPA06006862A (es) * | 2003-12-22 | 2007-01-26 | Alcon Inc | Agentes para el tratamiento de la retinopatia diabetica y formacion de drusen en degeneracion macular. |
| DE602004005617T2 (de) * | 2003-12-22 | 2007-12-13 | Alcon Inc. | Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
-
2004
- 2004-12-17 DE DE602004005617T patent/DE602004005617T2/de not_active Expired - Lifetime
- 2004-12-17 AU AU2004308919A patent/AU2004308919B2/en not_active Ceased
- 2004-12-17 ZA ZA200604862A patent/ZA200604862B/en unknown
- 2004-12-17 PL PL07105047T patent/PL1803468T3/pl unknown
- 2004-12-17 EP EP07105047A patent/EP1803468B1/en not_active Expired - Lifetime
- 2004-12-17 SI SI200430296T patent/SI1696958T1/sl unknown
- 2004-12-17 US US11/015,888 patent/US20050137146A1/en not_active Abandoned
- 2004-12-17 AT AT07105047T patent/ATE523208T1/de active
- 2004-12-17 WO PCT/US2004/042687 patent/WO2005063295A1/en not_active Ceased
- 2004-12-17 DK DK07105047.0T patent/DK1803468T3/da active
- 2004-12-17 AT AT04814825T patent/ATE357932T1/de active
- 2004-12-17 SI SI200431767T patent/SI1803468T1/sl unknown
- 2004-12-17 EP EP04814825A patent/EP1696958B1/en not_active Expired - Lifetime
- 2004-12-17 PT PT04814825T patent/PT1696958E/pt unknown
- 2004-12-17 PT PT07105047T patent/PT1803468E/pt unknown
- 2004-12-17 KR KR1020067014097A patent/KR20060127043A/ko not_active Ceased
- 2004-12-17 CA CA002547852A patent/CA2547852A1/en not_active Abandoned
- 2004-12-17 BR BRPI0417987-0A patent/BRPI0417987A/pt not_active IP Right Cessation
- 2004-12-17 DK DK04814825T patent/DK1696958T3/da active
- 2004-12-17 ES ES07105047T patent/ES2371364T3/es not_active Expired - Lifetime
- 2004-12-17 ES ES04814825T patent/ES2282926T3/es not_active Expired - Lifetime
- 2004-12-17 MX MXPA06006980A patent/MXPA06006980A/es active IP Right Grant
- 2004-12-17 PL PL04814825T patent/PL1696958T3/pl unknown
- 2004-12-17 JP JP2006545535A patent/JP4755599B2/ja not_active Expired - Fee Related
- 2004-12-17 CN CNA2004800384580A patent/CN1897972A/zh active Pending
-
2007
- 2007-05-25 CY CY20071100711T patent/CY1106623T1/el unknown
-
2010
- 2010-11-04 JP JP2010247809A patent/JP2011046736A/ja not_active Withdrawn
-
2011
- 2011-02-22 US US13/031,742 patent/US20110144127A1/en not_active Abandoned
- 2011-11-24 CY CY20111101143T patent/CY1112393T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1696958T3 (da) | Midler til behandling af glaukomatös retinopati og optiske neuropati | |
| CY1107181T1 (el) | Συνδυασμος ζιζανιοκτονων με ακυλιωμενες αμινοφαινυλοσουλφονυλουριες | |
| ATE505201T1 (de) | Enzymbehandlung von nahrungsmitteln für zöliakie- sprue | |
| NO20034094L (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
| DE602004008105D1 (de) | 42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen | |
| PT762837E (pt) | Processo para melhorar a durabilidade e/ou estabilizacao de produtos degradaveis microbiologicamente | |
| BRPI0417996A (pt) | agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular | |
| AR033232A1 (es) | Agentes herbicidas sinergicos que contienen herbicidas seleccionados entre el grupo de las benzoilciclohexano-dionas para su empleo en cultivos de arroz | |
| NO20052359D0 (no) | Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser | |
| GT200800066A (es) | Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento. | |
| AR032548A1 (es) | Metodo y composicion para desinfectar una superficie contaminada con una proteina prion | |
| HN2005000188S1 (es) | Diseño de confite (candy-dove disc) | |
| ES2126795T3 (es) | Formulacion y procedimiento de control de los nematodos parasitos de las plantas. | |
| BR0313186A (pt) | Agente redutor de colesterol proveniente de fibra alimentar e substâncias redutoras de colesterol | |
| BRPI0506631B8 (pt) | combinações, composição farmacêutica e usos das combinações | |
| AR034508A1 (es) | Agente protector de las neuronas retinales. | |
| ATE526992T1 (de) | Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung | |
| NO20030021L (no) | Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV | |
| AR011476A1 (es) | Nitrometilcetonas, su procedimiento de preparacion, composiciones que las contienen y su utilizacion para preparar medicamentos. | |
| BR0313543A (pt) | 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b | |
| GT200300260A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes | |
| UY27931A1 (es) | 2,3-dihidro-isoindol-1-onas | |
| BRMU8500905U (pt) | disposição construtiva introduzida em rolamento | |
| AR021749A1 (es) | Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas. | |
| WO2004087044A3 (en) | Drug target |